Literature DB >> 25398280

Cure model survival analysis after hepatic resection for colorectal liver metastases.

Alessando Cucchetti1, Alessandro Ferrero, Matteo Cescon, Matteo Donadon, Nadia Russolillo, Giorgio Ercolani, Giacomo Stacchini, Federico Mazzotti, Guido Torzilli, Antonio Daniele Pinna.   

Abstract

BACKGROUND: Statistical cure is achieved when a patient population has the same mortality as cancer-free individuals; however, data regarding the probability of cure after hepatectomy of colorectal liver metastases (CLM) have never been provided. We aimed to assess the probability of being statistically cured from CLM by hepatic resection.
METHODS: Data from 1,012 consecutive patients undergoing curative resection for CLM (2001-2012) were used to fit a nonmixture cure model to compare mortality after surgery to that expected for the general population matched by sex and age.
RESULTS: The 5- and 10-year disease-free survival was 18.9 and 15.8 %; the corresponding overall survival was 44.3 and 32.7 %. In the entire study population, the probability of being cured from CLM was 20 % (95 % confidence interval 16.5-23.5). After the first year, the mortality excess of resected patients, in comparison to the general population, starts to decline until it approaches zero 6 years after surgery. After 6.48 years, patients alive without tumor recurrence can be considered cured with 99 % certainty. Multivariate analysis showed that cure probabilities range from 40.9 % in patients with node-negative primary tumors and metachronous presentation of a single lesion <3 cm, to 1.5 % in patients with node positivity, and synchronous presentation of multiple, large CLMs. A model for the calculation of a cure fraction for each possible clinical scenario is provided.
CONCLUSIONS: Using a cure model, the present results indicate that statistical cure of CLM is possible after hepatectomy; providing this information can help clinicians give more precise answer to patients' questions.

Entities:  

Mesh:

Year:  2014        PMID: 25398280     DOI: 10.1245/s10434-014-4234-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  21 in total

Review 1.  [Surgical innovations in treatment of metastatic colorectal cancer : Complexity of metastatic surgery as example for personalized medicine].

Authors:  C Hackl; S M Brunner; K M Schmidt; H J Schlitt
Journal:  Chirurg       Date:  2018-03       Impact factor: 0.955

2.  Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.

Authors:  G Passot; Y S Chun; S E Kopetz; M J Overman; C Conrad; T A Aloia; J-N Vauthey
Journal:  Eur J Surg Oncol       Date:  2016-03-05       Impact factor: 4.424

3.  Failure to Cure Patients with Colorectal Liver Metastases: The Impact of the Liver Surgeon.

Authors:  Eduardo A Vega; Omid Salehi; Diana Nicolaescu; Edward-Michael Dussom; Sylvia V Alarcon; Olga Kozyreva; Jana Simonds; Deborah Schnipper; Claudius Conrad
Journal:  Ann Surg Oncol       Date:  2021-04-30       Impact factor: 5.344

4.  A Low Neutrophil to Lymphocyte Ratio Before Preoperative Chemotherapy Predicts Good Outcomes After the Resection of Colorectal Liver Metastases.

Authors:  Rui Mao; Jian-Jun Zhao; Xin-Yu Bi; Ye-Fan Zhang; Zhi-Yu Li; Zhen Huang; Jian-Guo Zhou; Hong Zhao; Jian-Qiang Cai
Journal:  J Gastrointest Surg       Date:  2018-07-31       Impact factor: 3.452

Review 5.  Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients.

Authors:  Matteo Donadon; Nina Cortese; Federica Marchesi; Matteo Cimino; Alberto Mantovani; Guido Torzilli
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

6.  Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival.

Authors:  Matteo Donadon; Kelly Hudspeth; Matteo Cimino; Luca Di Tommaso; Max Preti; Paolo Tentorio; Massimo Roncalli; Domenico Mavilio; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2017-05-23       Impact factor: 3.452

7.  Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status.

Authors:  B C Odisio; S Yamashita; S Y Huang; S Harmoush; S E Kopetz; K Ahrar; Y Shin Chun; C Conrad; T A Aloia; S Gupta; M E Hicks; J-N Vauthey
Journal:  Br J Surg       Date:  2017-02-27       Impact factor: 6.939

Review 8.  Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases.

Authors:  Guillaume Passot; Olivier Soubrane; Felice Giuliante; Giuseppe Zimmitti; Diane Goéré; Suguru Yamashita; Jean-Nicolas Vauthey
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

9.  Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy.

Authors:  Raja R Narayan; Jashodeep Datta; Debra A Goldman; Victoria G Aveson; Henry S Walch; Francisco Sanchez-Vega; Mithat Gönen; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham; Alice C Wei; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2022-07-27       Impact factor: 4.339

10.  Time to Incurable Recurrence for Patients Treated With Pulmonary Metastasectomy for Colorectal Cancer.

Authors:  Haruhisa Matsuguma; Mingyon Mun; Atsushi Sano; Ichiro Yoshino; Hiroshi Hashimoto; Yasushi Shintani; Tomohiko Iida; Satoshi Shiono; Masayuki Chida; Hiroaki Kuroda; Mitsuo Nakayama; Yuji Shiraishi; Kazuhito Funai; Masafumi Kawamura
Journal:  Ann Surg Oncol       Date:  2022-06-18       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.